These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 34744712)

  • 1. Experience of a Strategy Including CYP2C19 Preemptive Genotyping Followed by Therapeutic Drug Monitoring of Voriconazole in Patients Undergoing Allogenic Hematopoietic Stem Cell Transplantation.
    García-García I; Dapía I; Montserrat J; Martinez de Soto L; Bueno D; Díaz L; Queiruga J; Rodriguez Mariblanca A; Guerra-García P; Ramirez E; Frías J; Pérez Martínez A; Carcas-Sansuan AJ; Borobia AM
    Front Pharmacol; 2021; 12():717932. PubMed ID: 34744712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.
    Resztak M; Zalewska P; Wachowiak J; Sobkowiak-Sobierajska A; Główka FK
    Eur J Clin Pharmacol; 2024 Nov; 80(11):1829-1840. PubMed ID: 39240338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring and
    Chen X; Xiao Y; Li H; Huang Z; Gao J; Zhang X; Li Y; Van Timothee BM; Feng X
    Transl Pediatr; 2022 Aug; 11(8):1311-1322. PubMed ID: 36072540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections.
    Lamoureux F; Duflot T; Woillard JB; Metsu D; Pereira T; Compagnon P; Morisse-Pradier H; El Kholy M; Thiberville L; Stojanova J; Thuillez C
    Int J Antimicrob Agents; 2016 Feb; 47(2):124-31. PubMed ID: 26775563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation.
    Teusink A; Vinks A; Zhang K; Davies S; Fukuda T; Lane A; Nortman S; Kissell D; Dell S; Filipovich A; Mehta P
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):482-6. PubMed ID: 26616742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of CYP2C19 genotype with plasma voriconazole exposure in South-western Chinese Han patients with invasive fungal infections.
    Miao Q; Tang JT; van Gelder T; Li YM; Bai YJ; Zou YG; Wang LL; Shi YY
    Medicine (Baltimore); 2019 Jan; 98(3):e14137. PubMed ID: 30653146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of a mathematical prediction model for voriconazole stable maintenance dose: a prospective study.
    Zhou L; Li M; Li H; Guo Z; Gao Y; Zhang H; Qin F; Sang Z; Xing Q; Cheng L; Cao W
    Front Cell Infect Microbiol; 2023; 13():1157944. PubMed ID: 37565064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients.
    Takahashi T; Smith AR; Jacobson PA; Fisher J; Rubin NT; Kirstein MN
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Combined Effect of CYP2C19 Genetic Polymorphism and Proton Pump Inhibitors Coadministration on Trough Concentration of Voriconazole.
    Mafuru M; Wu S; Mayala H; Msengwa Z; Phillip A; Mgone C
    Pharmgenomics Pers Med; 2021; 14():1379-1389. PubMed ID: 34754219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
    Hu L; Huang Q; Huang S; Feng Z
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective CYP2C19-Guided Voriconazole Prophylaxis in Patients With Neutropenic Acute Myeloid Leukemia Reduces the Incidence of Subtherapeutic Antifungal Plasma Concentrations.
    Hicks JK; Quilitz RE; Komrokji RS; Kubal TE; Lancet JE; Pasikhova Y; Qin D; So W; Caceres G; Kelly K; Salchert YS; Shahbazian K; Abbas-Aghababazadeh F; Fridley BL; Velez AP; McLeod HL; Greene JN
    Clin Pharmacol Ther; 2020 Mar; 107(3):563-570. PubMed ID: 31549389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
    Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
    Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.
    Patel JN; Robinson M; Morris SA; Jandrisevits E; Lopes KE; Hamilton A; Steuerwald N; Druhan LJ; Avalos B; Copelan E; Ghosh N; Grunwald MR
    Pharmacogenomics J; 2023 Nov; 23(6):201-209. PubMed ID: 37925536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic drug interaction between tacrolimus and lansoprazole in a bone marrow transplant patient receiving voriconazole and harboring CYP2C19 and CYP3A5 heterozygous mutations.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Katayama N; Okuda M
    Clin Ther; 2011 Aug; 33(8):1077-80. PubMed ID: 21802143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies.
    Resztak M; Sobiak J; Czyrski A
    Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.
    Moriyama B; Kadri S; Henning SA; Danner RL; Walsh TJ; Penzak SR
    Curr Fungal Infect Rep; 2015 Jun; 9(2):74-87. PubMed ID: 26918067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
    Moriyama B; Obeng AO; Barbarino J; Penzak SR; Henning SA; Scott SA; Agúndez J; Wingard JR; McLeod HL; Klein TE; Cross SJ; Caudle KE; Walsh TJ
    Clin Pharmacol Ther; 2017 Jul; 102(1):45-51. PubMed ID: 27981572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.
    Dapía I; García I; Martinez JC; Arias P; Guerra P; Díaz L; García A; Ochoa D; Tenorio J; Ramírez E; Román M; Gordo G; Saiz-Rodríguez M; Frías J; Abad-Santos F; Lapunzina P; Carcas AJ; Borobia AM
    Int J Antimicrob Agents; 2019 Oct; 54(4):463-470. PubMed ID: 31279853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Therapeutic Drug Monitoring and Cytochrome P450 2C19 Genotyping on Clinical Outcomes of Voriconazole: A Systematic Review.
    Lee J; Ng P; Hamandi B; Husain S; Lefebvre MJ; Battistella M
    Ann Pharmacother; 2021 Apr; 55(4):509-529. PubMed ID: 32772568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.
    Sienkiewicz B; Urbaniak-Kujda D; Dybko J; Dryś A; Hurkacz M; Wróbel T; Wiela-Hojeńska A
    Pathol Oncol Res; 2018 Jul; 24(3):541-545. PubMed ID: 28685218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.